Cipla to buy 21.85 pc stake in health-tech startup GoApptiv

In the first stage, a subscription of 15,392 compulsorily convertible preference shares and purchase of 6,927 equity shares is expected to be closed within 30 days from the execution date, subject to certain conditions precedent, In the second stage, "subscription of 12,314 compulsorily convertible preference shares is expected to close by October 31, subject to certain conditions precedent," Cipla added.

Published On 2020-06-10 06:59 GMT   |   Update On 2021-11-22 17:45 GMT
Advertisement

Mumbai: Pharma major Cipla on Wednesday said it will acquire a 21.85 percent stake in GoApptiv on a fully-diluted basis in two phases. The cost of acquisition is Rs 9 crore (Rs 5.80 crore in the first stage and Rs 3.20 crore in the second stage), it said in a regulatory filing.

In the first stage, a subscription of 15,392 compulsorily convertible preference shares and purchase of 6,927 equity shares is expected to be closed within 30 days from the execution date, subject to certain conditions precedent, In the second stage, "subscription of 12,314 compulsorily convertible preference shares is expected to close by October 31, subject to certain conditions precedent," it added.

Advertisement

GoApptiv offers digital solutions for integrated brand sales management, digital marketing, and channel engagement for pharmaceutical companies. It also provides digital solutions for customer relationship management, patient support, and healthcare data analytics.

Through an equity investment, representing a 21.85 percent stake in GoApptiv, the drug firm will strengthen its partnership with the firm so as to enable the widening reach of its key brands in the tier-3 plus towns, Cipla said. The shares of Cipla were trading at Rs 648.20 apiece on BSE in morning trade, up 1.30 percent from their previous close. 

Also Read: DoP Directs NPPA To Verify Documentary Proof Submitted By Cipla For Budesonide

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News